ROZVIN F 20/160

ROZVIN F 20/160 — Rosuvastatin 20 mg + Fenofibrate 160 mg Tablets

Overview

ROZVIN F 20/160 is a combination lipid-lowering therapy that combines Rosuvastatin 20 mg, a potent statin, with Fenofibrate 160 mg, a fibrate derivative. This dual-action formulation is designed to effectively manage mixed dyslipidemia, helping to lower LDL cholesterol, triglycerides, and total cholesterol while increasing HDL cholesterol.

ROZVIN F 20/160 is particularly suitable for patients with high cardiovascular risk, severe dyslipidemia, or inadequate response to monotherapy, providing comprehensive lipid control in a single tablet.

Composition

Each tablet contains:

• Rosuvastatin 20 mg – HMG-CoA reductase inhibitor that reduces LDL cholesterol, total cholesterol, and triglycerides while increasing HDL cholesterol.

• Fenofibrate 160 mg – Activates peroxisome proliferator-activated receptor alpha (PPAR-α), reducing triglycerides and VLDL levels while improving HDL cholesterol.

Dosage Form

• Tablet

Therapeutic Class

• Lipid-Lowering Combination Therapy / Statin + Fibrate

Indications

ROZVIN F 20/160 Tablets are indicated for:

• Mixed dyslipidemia (elevated LDL and triglycerides)

• Patients with hypercholesterolemia not adequately controlled by monotherapy

• Prevention of cardiovascular events in high-risk patients

• Adjunct therapy to diet and lifestyle modifications for comprehensive lipid management

Mechanism of Action

• Rosuvastatin inhibits the HMG-CoA reductase enzyme, lowering cholesterol synthesis in the liver and improving LDL/HDL balance.

• Fenofibrate activates PPAR-α, enhancing lipid metabolism, reducing triglycerides and VLDL, and increasing HDL cholesterol.

• The combination provides synergistic effects, offering enhanced control of multiple lipid parameters for better cardiovascular protection.

Dosage and Administration

• Recommended Dose: As prescribed by the physician, usually once daily

• Route: Oral

• Duration: Long-term therapy as advised by a healthcare provider

Note: Regular monitoring of lipid profile, liver function, and renal function is recommended during therapy.

Benefits

• Lowers LDL cholesterol and triglycerides

• Increases HDL cholesterol

• Helps prevent atherosclerosis, heart attack, and stroke

• Suitable for patients with mixed dyslipidemia or high cardiovascular risk

• Convenient once-daily tablet improves adherence

Side Effects

ROZVIN F 20/160 is generally well tolerated. Possible side effects include:

• Mild gastrointestinal disturbances (nausea, abdominal discomfort)

• Headache or dizziness

• Muscle pain or weakness (rare, associated with statins)

• Liver enzyme elevation (rare)

Patients should consult their physician if side effects persist.

Precautions

• Avoid in patients with active liver disease or severe renal impairment

• Not recommended during pregnancy or lactation

• Inform your doctor about other medications to prevent interactions

• Regular monitoring of liver and kidney function is advised during therapy

Storage

Store below 25°C, in a dry place away from sunlight. Keep out of reach of children.

Key Product Information

• Brand Name: ROZVIN F 20/160

• Composition: Rosuvastatin 20 mg + Fenofibrate 160 mg

• Dosage Form: Tablet

• Therapeutic Class: Lipid-Lowering Combination Therapy / Statin + Fibrate

• Manufacturer: [Insert Company Name]

• Packaging: [Example: 10×10 Tablets / Strip]

Why Choose ROZVIN F 20/160

• Combines statin and fibrate therapy for enhanced lipid control

• Provides comprehensive management of mixed dyslipidemia

• Convenient once-daily dosing improves compliance

• Manufactured under strict GMP-certified quality standards

Conclusion

ROZVIN F 20/160 (Rosuvastatin 20 mg + Fenofibrate 160 mg Tablets) offers dual lipid-lowering therapy for patients with mixed dyslipidemia or high cardiovascular risk. By reducing LDL and triglycerides while increasing HDL cholesterol, it supports heart health, prevents atherosclerosis, and reduces the risk of cardiovascular events, providing comprehensive long-term lipid management.